Advertisement
American Journal of Kidney Diseases

Biomarkers of Vitamin D Status and Risk of ESRD

Published:October 13, 2015DOI:https://doi.org/10.1053/j.ajkd.2015.08.026

      Background

      Disordered mineral metabolism is characteristic of decreased kidney function. However, the prospective associations between circulating levels of vitamin D binding protein, vitamin D, and end-stage renal disease (ESRD) have not been extensively evaluated in epidemiologic studies.

      Study Design

      Nested case-control study.

      Setting & Participants

      Middle-aged black and white men and women from 4 US communities.

      Predictors

      Baseline levels of vitamin D binding protein, 25-hydroxyvitamin D (25[OH]D), and 1,25-dihydroxyvitamin D (1,25[OH]2D) were measured in blood samples collected at study visit 4 (1996-1998) of the ARIC (Atherosclerosis Risk in Communities) Study.

      Outcome

      ESRD cases (n = 184) were identified through hospitalization diagnostic codes from 1996 to 2008 and were frequency matched to controls (n = 251) on categories of estimated glomerular filtration rate, albuminuria, diabetes mellitus, sex, and race.

      Measurements

      Logistic regression was used to estimate the association between mineral metabolism biomarkers (vitamin D binding protein, 25(OH)D, and 1,25(OH)2D) and incident ESRD, adjusting for age, sex, race, estimated glomerular filtration rate, albuminuria, diabetes mellitus, hypertension, education, specimen type, and serum levels of calcium, phosphate, and parathyroid hormone.

      Results

      Higher vitamin D binding protein levels were associated with elevated risk for incident ESRD (OR, 1.76; 95% CI, 1.22-2.54; P = 0.003). Higher free and bioavailable 25(OH)D levels were associated with reduced risk for incident ESRD (ORs of 0.65 [95% CI, 0.46-0.92; P = 0.02] and 0.63 [95% CI, 0.43-0.91; P = 0.02] for free and bioavailable 25[OH]D, respectively). There was no association between ESRD and overall levels of 25(OH)D (OR, 0.83; 95% CI, 0.58-1.19; P = 0.3) or 1,25(OH)2D (OR, 0.73; 95% CI, 0.48-1.13; P = 0.2).

      Limitations

      Lack of direct measurement of free and bioavailable vitamin D.

      Conclusions

      In the general population, blood levels of vitamin D binding protein were positively associated and blood levels of free and bioavailable 25(OH)D were inversely associated with new-onset ESRD during follow-up.

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Craver L.
        • Marco M.P.
        • Martinez I.
        • et al.
        Mineral metabolism parameters throughout chronic kidney disease stages 1-5—achievement of K/DOQI target ranges.
        Nephrol Dial Transplant. 2007; 22: 1171-1176
        • Scialla J.J.
        • Astor B.C.
        • Isakova T.
        • Xie H.
        • Appel L.J.
        • Wolf M.
        Mineral metabolites and CKD progression in African Americans.
        J Am Soc Nephrol. 2013; 24: 125-135
        • Levin A.
        • Bakris G.L.
        • Molitch M.
        • et al.
        Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.
        Kidney Int. 2007; 71: 31-38
        • Doorenbos C.R.
        • van den Born J.
        • Navis G.
        • de Borst M.H.
        Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism.
        Nat Rev Nephrol. 2009; 5: 691-700
        • Koizumi M.
        • Komaba H.
        • Fukagawa M.
        Parathyroid function in chronic kidney disease: role of FGF23-klotho axis.
        Contrib Nephrol. 2013; 180: 110-123
        • Reinhardt W.
        • Dolff S.
        • John P.
        • Kribben A.
        • Witzke O.
        Impact of renal failure on metabolic bone parameters in a vitamin D-deficient patient cohort.
        Clin Nephrol. 2011; 75: 403-409
        • National Kidney Foundation
        KDOQI clinical practice guideline for diabetes and CKD: 2012 update.
        Am J Kidney Dis. 2012; 60: 850-886
        • Kandula P.
        • Dobre M.
        • Schold J.D.
        • Schreiber Jr., M.J.
        • Mehrotra R.
        • Navaneethan S.D.
        Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials.
        Clin J Am Soc Nephrol. 2011; 6: 50-62
        • Ravani P.
        • Malberti F.
        • Tripepi G.
        • et al.
        Vitamin D levels and patient outcome in chronic kidney disease.
        Kidney Int. 2009; 75: 88-95
        • Melamed M.L.
        • Astor B.
        • Michos E.D.
        • Hostetter T.H.
        • Powe N.R.
        • Muntner P.
        25-Hydroxyvitamin D levels, race, and the progression of kidney disease.
        J Am Soc Nephrol. 2009; 20: 2631-2639
        • Bikle D.D.
        • Siiteri P.K.
        • Ryzen E.
        • Haddad J.G.
        Serum protein binding of 1,25-dihydroxyvitamin D: a reevaluation by direct measurement of free metabolite levels.
        J Clin Endocrinol Metab. 1985; 61: 969-975
        • Mendel C.M.
        The free hormone hypothesis: a physiologically based mathematical model.
        Endocr Rev. 1989; 10: 232-274
        • Bhan I.
        • Powe C.E.
        • Berg A.H.
        • et al.
        Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients.
        Kidney Int. 2012; 82: 84-89
        • Bikle D.D.
        • Gee E.
        • Halloran B.
        • Kowalski M.A.
        • Ryzen E.
        • Haddad J.G.
        Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein.
        J Clin Endocrinol Metab. 1986; 63: 954-959
        • Arnaud J.
        • Constans J.
        Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP).
        Hum Genet. 1993; 92: 183-188
        • Powe C.E.
        • Evans M.K.
        • Wenger J.
        • et al.
        Vitamin D-binding protein and vitamin D status of black Americans and white Americans.
        N Engl J Med. 2013; 369: 1991-2000
        • Lutsey P.L.
        • Eckfeldt J.H.
        • Ogagarue E.R.
        • Folsom A.R.
        • Michos E.D.
        • Gross M.
        The 25-hydroxyvitamin D3 C-3 epimer: distribution, correlates, and reclassification of 25-hydroxyvitamin D status in the population-based Atherosclerosis Risk in Communities Study (ARIC).
        Clin Chim Acta. 2015; 442: 75-81
        • ARIC Investigators The
        The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives.
        Am J Epidemiol. 1989; 129: 687-702
        • Bash L.D.
        • Coresh J.
        • Kottgen A.
        • et al.
        Defining incident chronic kidney disease in the research setting: the ARIC Study.
        Am J Epidemiol. 2009; 170: 414-424
        • Levey A.S.
        • Stevens L.A.
        • Schmid C.H.
        • et al.
        A new equation to estimate glomerular filtration rate.
        Ann Intern Med. 2009; 150: 604-612
        • Laha T.J.
        • Strathmann F.G.
        • Wang Z.
        • de Boer I.H.
        • Thummel K.E.
        • Hoofnagle A.N.
        Characterizing antibody cross-reactivity for immunoaffinity purification of analytes prior to multiplexed liquid chromatography-tandem mass spectrometry.
        Clin Chem. 2012; 58: 1711-1716
        • Musunuru K.
        • Lettre G.
        • Young T.
        • et al.
        Candidate gene association resource (CARe): design, methods, and proof of concept.
        Circ Cardiovasc Genet. 2010; 3: 267-275
        • Vermeulen A.
        • Verdonck L.
        • Kaufman J.M.
        A critical evaluation of simple methods for the estimation of free testosterone in serum.
        J Clin Endocrinol Metab. 1999; 84: 3666-3672
        • Braun A.
        • Bichlmaier R.
        • Cleve H.
        Molecular analysis of the gene for the human vitamin-D-binding protein (group-specific component): allelic differences of the common genetic GC types.
        Hum Genet. 1992; 89: 401-406
        • Safadi F.F.
        • Thornton P.
        • Magiera H.
        • et al.
        Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein.
        J Clin Invest. 1999; 103: 239-251
        • Bikle D.D.
        • Gee E.
        Free, and not total, 1,25-dihydroxyvitamin D regulates 25-hydroxyvitamin D metabolism by keratinocytes.
        Endocrinology. 1989; 124: 649-654
        • Holick M.F.
        • Binkley N.C.
        • Bischoff-Ferrari H.A.
        • et al.
        Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline.
        J Clin Endocrinol Metab. 2011; 96: 1911-1930
        • Al-Badr W.
        • Martin K.J.
        Vitamin D and kidney disease.
        Clin J Am Soc Nephrol. 2008; 3: 1555-1560
        • Holick M.F.
        Vitamin D deficiency.
        N Engl J Med. 2007; 357: 266-281
        • Dominguez J.R.
        • Shlipak M.G.
        • Whooley M.A.
        • Ix J.H.
        Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes.
        J Am Soc Nephrol. 2013; 24: 647-654
        • Nakanishi S.
        • Kazama J.J.
        • Nii-Kono T.
        • et al.
        Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.
        Kidney Int. 2005; 67: 1171-1178
        • Shimada T.
        • Hasegawa H.
        • Yamazaki Y.
        • et al.
        FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.
        J Bone Miner Res. 2004; 19: 429-435
        • Uzum A.K.
        • Salman S.
        • Telci A.
        • et al.
        Effects of vitamin D replacement therapy on serum FGF23 concentrations in vitamin D-deficient women in short term.
        Eur J Endocrinol. 2010; 163: 825-831
        • Turner C.
        • Dalton N.
        • Inaoui R.
        • Fogelman I.
        • Fraser W.D.
        • Hampson G.
        Effect of a 300 000-IU loading dose of ergocalciferol (vitamin D2) on circulating 1,25(OH)2-vitamin D and fibroblast growth factor-23 (FGF-23) in vitamin D insufficiency.
        J Clin Endocrinol Metab. 2013; 98: 550-556
        • Rebholz C.M.
        • Grams M.E.
        • Coresh J.
        • et al.
        Serum fibroblast growth factor-23 is associated with incident kidney disease.
        J Am Soc Nephrol. 2015; 26: 192-200
        • Adema A.Y.
        • de Borst M.H.
        • Ter Wee P.M.
        • Vervloet M.G.
        • NIGRAM Consortium
        Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.
        J Ren Nutr. 2014; 24: 143-150
        • Taal M.W.
        • Thurston V.
        • McIntyre N.J.
        • Fluck R.J.
        • McIntyre C.W.
        The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.
        Kidney Int. 2014; 86: 407-413
        • Agborsangaya C.
        • Toriola A.T.
        • Grankvist K.
        • et al.
        The effects of storage time and sampling season on the stability of serum 25-hydroxy vitamin D and androstenedione.
        Nutr Cancer. 2010; 62: 51-57
        • Bash L.D.
        • Astor B.C.
        • Coresh J.
        Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study.
        Am J Kidney Dis. 2010; 55: 31-41
        • Rebholz C.M.
        • Coresh J.
        • Ballew S.H.
        • et al.
        Kidney failure and ESRD in the Atherosclerosis Risk in Communities (ARIC) Study: comparing ascertainment of treated and untreated kidney failure in a cohort study.
        Am J Kidney Dis. 2015; 66: 231-239